Cartridge-based sequencing for bedaquiline resistance detection from sputum by J.D. Limberis, R.J. Nagel, D. Block, R.E. Colman, A. Nalyvayko, Z. Howard, S. Dewell, S. Chakravorty, J.Z. Metcalfe

Subjects: Get full text

Impact of bedaquiline resistance probability on treatment decision for rifampicin-resistant TB by T.P.H. Trang, R. Kessels, T. Decroo, A. Van Rie

“…BACKGROUND: Accurate diagnosis of bedaquiline (BDQ) resistance remains challenging. A Bayesian approach expresses this uncertainty as a probability of BDQ resistance (prBDQR) with a 95% credible interval. …”
Get full text

Mice infected with M. tuberculosis with Rv0678 mutations still benefit from bedaquiline treatment by N. Lounis, T. Gevers, C. Villellas, K. Andries

Get full text

Development of tolerance to bedaquiline by overexpression of trypanosomal acetate: succinate CoA transferase in Mycobacterium smegmatis by Gloria Mavinga Bundutidi, Kota Mochizuki, Yuichi Matsuo, Mizuki Hayashishita, Takaya Sakura, Yuri Ando, Gregory Murray Cook, Acharjee Rajib, Frédéric Bringaud, Michael Boshart, Shinjiro Hamano, Masakazu Sekijima, Kenji Hirayama, Kiyoshi Kita, Daniel Ken Inaoka

“…Abstract The F-type ATP synthase inhibitor bedaquiline (BDQ) is a potent inhibitor of mycobacterial growth and this inhibition cannot be rescued by fermentable carbon sources that would supply ATP by an alternative pathway (substrate level phosphorylation). …”
Get full text

Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review by Denise Rossato Silva, Flávia Fonseca Fernandes, Juliana Carvalho Ferreira, Wanderley Bernando, Margareth Maria Pretti Dalcolmo, Fernanda Dockhorn Costa Johansen, Fernanda Carvalho de Queiroz Mello

“…ABSTRACT Objective: To evaluate the available evidence comparing the use of the bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) regimen for 6 months with that of standard-of-care regimens for patients with multidrug-resistant or rifampin-resistant tuberculosis (MDR/RR-TB). …”
Get full text

Effects of Bedaquiline on Antimicrobial Activity and Cytokine Secretion of Macrophages Infected with Multidrug-Resistant Mycobacterium tuberculosis Strains by Xia-Li Lyu, Ting-Ting Lin, Jing-Tao Gao, Hong-Yan Jia, Chuan-Zhi Zhu, Zi-Hui Li, Jing Dong, Qi Sun, Wei Shu, Sai-Sai Wang, Li-Ping Pan, Hai-Rong Huang, Zong-De Zhang, Qi Li

“…Background. Bedaquiline (Bdq) exerts bactericidal effects against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains, including multidrug-resistant M. tuberculosis strains (MDR-MTBs). …”
Get full text

Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines by D. Evans, K. Hirasen, D.J. Casalme, M.T. Gler, A. Gupta, S. Juneja

Subjects: “…bedaquiline…”
Get full text

Mycobacterium tuberculosis Lineage Distribution Using Whole-Genome Sequencing and Bedaquiline, Clofazimine, and Linezolid Phenotypic Profiles among Rifampicin-Resistant Isolates from West Java, Indonesia by Andriansjah Rukmana, Cynthia Gozali, Linda Erlina

“…The isolates showed phenotypically resistance to bedaquiline, clofazimine, and linezolid at 5%, 0%, and 0%, respectively. …”
Get full text

Experience of piloting BPaLM/BPaL for DR-TB care at selected sites in Pakistan by M.A. Khan, A. Ismail, A. Ghafoor, N. Khan, N. Muzaffar, F. Zafar, A. Gupta, S. Foraida, S. Juneja, R. Fatima, A.W. Khan, S. Shahid, M.A. Khan

Subjects: Get full text

Comprehensive genomic surveillance reveals transmission profiles of extensively drug-resistant tuberculosis cases in Pará, Brazil by Davi Josué Marcon, Davi Josué Marcon, Abhinav Sharma, Alex Brito Souza, Alex Brito Souza, Rafaella Bonfim Barros, Valnete das Graças Dantas Andrade, Ricardo José de Paula Souza Guimarães, Luana Nepomuceno Gondim Lima, Luana Nepomuceno Gondim Lima, Lúcia Helena Martins Tavares Monteiro, Ana Judith Pires Garcia Quaresma, Ana Judith Pires Garcia Quaresma, Layana Rufino Ribeiro, Layana Rufino Ribeiro, Philip Noel Suffys, Robin Mark Warren, Carlos Augusto Abreu Alberio, Karla Valéria Batista Lima, Karla Valéria Batista Lima, Emilyn Costa Conceição

Subjects: “…bedaquiline…”
Get full text

Savings from the introduction of BPaL and BPaLM regimens at the country level by C. Auer, A. Gupta, C. Malbacius, A. Ghafoor, Y. Kock, O. Medvedieva, P. Hanlon, P. Steinmann, S. Juneja

Subjects: Get full text

TB drug susceptibility testing in high fluoroquinolone resistance settings by F. Saluzzo, F. Masood, V. Batignani, F. Di Marco, U. Majeed, A. Ghazal, D.M. Cirillo, S. Tahseen

“…BACKGROUND: The insurgence of resistance to key drugs of the BPaLM (bedaquiline + pretomanid + moxifloxacin) regimen is a major concern. …”
Get full text

Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan by S. Moe, I. Azamat, S. Allamuratova, M. Oluya, A. Khristusev, M.L. Rekart, K. Mamitova, G. Bidwell, C. Gomez-Restrepo, B. Kalmuratov, Z. Tigay, N. Parpieva, K. Safaev, N. Sitali, D. Gomez, A. Mikhail, A. Sinha

“…Prevalence of resistance to bedaquiline, linezolid, moxifloxacin, levofloxacin, and amikacin were respectively 3.1%, 0.8%, 15%, 13%, and 12%. …”
Get full text

Efficacy of carbonyl cyanide-3-chlorophenylhydrazone in combination with antibiotics against Mycobacterium abscessus by Jifang Zheng, Qiang Liu, Haoran Wang, Fengmin Huo, Junnan Jia, Hairong Huang, Suting Chen

“…When CCCP is paired with bedaquiline and clofazimine, it exhibits additive effects. …”
Get full text

Treating drug-resistant tuberculosis in an era of shorter regimens: Insights from rural South Africa by J-D K Lotz, J Porter, H Conradie, T Boyles, B Gaunt, S Dimanda, D Cort

“…Injectables (aOR 0.22, 95% CI 0.08 - 0.57), bedaquiline (aOR 0.05, 95% CI 0.01 - 0.19), increasing age (aOR 1.09, 95% CI 1.05 - 1.13), extra-pulmonary TB (aOR 8.15, 95% CI 1.62 - 41.03) and HIV viraemia (aOR 9.20, 95% CI 3.22 - 26.24) were all significantly and independently associated with mortality. …”
Get full text

Progress in programmatic management of drug-resistant TB, WHO Eastern Mediterranean Region, 2018-2023 by K. Bennani, M. van den Boom, M.G. ElMedrek, Y. Hutin

“…By 2023, fourteen countries had implemented all-oral regimens, with three initiating the 6-month bedaquiline, pretomanid, linezolid, and moxifloxacin regimen (BPaL(M)). …”
Get full text

Tuberculosis vaccines and therapeutic drug: challenges and future directions by Yajing An, Ruizi Ni, Li Zhuang, Ling Yang, Zhaoyang Ye, Linsheng Li, Seppo Parkkila, Ashok Aspatwar, Wenping Gong

“…Furthermore, the review delves into current TB therapeutics, particularly for multidrug-resistant tuberculosis (MDR-TB), exploring promising agents like bedaquiline (BDQ) and delamanid (DLM), as well as the potential of host-directed therapies. …”
Get full text

Cost-effectiveness of targeted next-generation sequencing (tNGS) for detection of tuberculosis drug resistance in India, South Africa and Georgia: a modeling analysisResearch in co... by Suvesh Shrestha, Angelina Addae, Cecily Miller, Nazir Ismail, Alice Zwerling

“…Scenario with 50% reduction in tNGS test kit costs made tNGS cost-effective across all three countries, while a high Bedaquiline resistance prevalence (30%) led to a worsening cost-effectiveness. …”
Get full text

Operational research as a mechanism to improve treatment outcomes for drug-resistant TB in the WHO European Region by G.B. Migliori, O. Korotych, J. Achar, A. Ciobanu, G. Dravniece, M. Germanovych, E. Gurbanova, A. Hovhannesyan, N. Khachatryan, L. Kuksa, N. Lomtadze, M.L. Rich, A. Skrahina, A. Yedilbayev

“…The three regimens were: 1) bedaquiline + linezolid + levofloxacin + clofazimine + cycloserine (BdqLzdLfxCfzCs); 2) BdqLzdLfxCfz + delamanid (Dlm) for children over 6 years of age and adults; and 3) DlmLzdLfxCfz for children under 6 years of age. …”
Get full text

Low body mass index as a predictor of sputum culture conversion and treatment outcomes among patients receiving treatment for multidrug-resistant tuberculosis in Lesotho by Lawrence Oyewusi, Chengbo Zeng, KJ Seung, Stephanie Mpinda, Mikanda Kunda, Carole D Mitnick, Makelele Kanu, Meseret Tamirat, Joalane Makaka, Mabatloung Mofolo, Refiloe Maime, Llang Maama, Ninza Senyo, Bamidele Oguntoyinbo, Lwayi Mayombo, Molly F Franke

“…Methods Secondary data from a prospective cohort of patients initiating a longer (18–20 months) treatment containing bedaquiline and/or delamanid under routine programmatic conditions in Lesotho were analysed. …”
Get full text